Clinical trialNCT07382375Not, yet, recruitingInterventional

AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection

SponsorNanjing Medical UniversityEnrollment300Aortic Aneurysm and Dissection

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Aortic dissection has acute onset and high mortality, with immunoinflammatory response driving lesion progression. Current perioperative anti-inflammatory therapies are mostly empirical and poorly targeted, and AI-assisted typing lacks a complete clinical translation pathway. This study integrates multi-dimensional data to construct an AI immunoinflammatory subtyping system, enabling rapid subtyping and establishing a "subtyping-target-treatment" closed loop for emergency needs. Using a prospective multicenter RCT, 300 patients are randomly divided into two groups: the experimental group receives subtyping-based precision therapy, while the control group uses empirical strategies (treatment of physician's choice). It observes 7-day postoperative SOFA score, SIRS and other prognostic indicators to provide evidence-based support for precision treatment.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Hong Liu
The First Affiliated Hospital with Nanjing Medical University
Principal Investigator
clinicaltrials.gov ↗
Yong-feng Shao
The First Affiliated Hospital with Nanjing Medical University
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China

Beijing Anzhen Hospital
Beijing, China
Hong-jia Zhang, MD
Changzhou First People Hospital
Changzhou, China
Chao Ma, MD
West China Hospital of Sichuan University
Chengdu, China
Hong-hua Yue, MD
Fujian Medical University Union Hospital
Fuzhou, China
Dong-dong Wu, MD
the First Affiliated Hospital of Guangzhou Medical University
Guangzhou, China
Ying-yuan Zhang, MD
Nanchang University Second Hospital
Nanchang, China
JI-SHENG Zhong, MD
the First Affiliated Hospital of Nanjing Medical University
Nanjing, China
Hong Liu, MD
Shanghai East Hospital
Shanghai, China
Guo-liang Fan, MD

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

UlinastatinUlinastatin and Thymalfasin

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Dec 2027
Primary completion: 31 Dec 2027
Completion: 31 Dec 2027
Last update posted: 2 Feb 2026
Registered enrollment: 300
Registry id: NCT07382375

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.